Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial - Concepedia

Concepedia

Publication | Open Access

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

DOI Full Paper Access

280

Citations

20

References

2022

Year

Alison Tree, Peter Ostler, H. van der Voet, William Chu, Andrew Loblaw, Daniel Ford, Shaun Tolan, Suneil Jain, Alexander S. Martin, John Staffurth,

The Lancet Oncology

Abstract

Accuray.

References

	Year	Citations

Page 1